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Abstract
Background: The SMART study was a trial of intermittent use of antiretroviral therapy (ART) (drug conservation [DC]) versus
continuous use of ART (viral suppression [VS]) as a strategy to reduce toxicities, including cardiovascular disease (CVD) risk.
We studied the predictive value of high sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6) and D-dimer with CVD
morbidity and mortality in HIV-infected patients who were enrolled in SMART beyond other measured CVD risk factors.
Methods: A blood sample was available in 5098 participants who were enrolled in the SMART study for the measurement of
IL-6, hsCRP and D-dimer. Hazard ratios (HR) with 95% CI for CVD events were estimated for each quartile (Q) for each
biomarker vs the 1st quartile and for 1 SD higher levels. For both treatment groups combined, unadjusted and adjusted HRs
were determined using Cox regression models.
Results: There were 252 participants who had a CVD event over a median follow-up of 29 months. Adjusted HRs (95% CI) for
CVD for Q4 vs Q1 were 4.65 (2.61, 8.29), 2.10 (1.40, 3.16), and 2.14 (1.38, 3.33) for IL-6, hsCRP and D-dimer, respectively.
Associations were similar for the DC and VS treatment groups (interaction p-values were .0.30). The addition of the three
biomarkers to a model that included baseline covariates significantly improved model fit (p,0.001). Area under the curve
(AUC) estimates improved with inclusion of the three biomarkers in a model that included baseline covariates
corresponding to other CVD risk factors and HIV factors (0.741 to 0.771; p,0.001 for difference).
Conclusions: In HIV-infected individuals, IL-6, hsCRP and D-dimer are associated with an increased risk of CVD independent
of other CVD risk factors. Further research is needed to determine whether these biomarkers can be used to improve CVD
risk prediction among HIV positive individuals.
Citation: Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, et al. (2012) Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals. PLoS
ONE 7(9): e44454. doi:10.1371/journal.pone.0044454
Editor: Claire Thorne, UCL Institute of Child Health, University College London, United Kingdom
Received May 1, 2012; Accepted August 3, 2012; Published September 10, 2012
Copyright:  2012 Duprez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Support for this work was provided by NIAD, United States National Institutes of Health grants UO1AI068641, U01AI042170, and U01AI046362. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts. Russell Tracy declares the following work: Merck – seminar
and consulting related to biomarkers in the setting of HIV; Abbott - seminar and consulting related to biomarkers in the setting of HIV; Tibotec-Johnson &
Johnson - consulting related to biomarkers in the setting of HIV. All authors except Dr. Tracy have declared that no competing interests exist. This does not alter
the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: dupre007@umn.edu
Introduction
Advances in the management of HIV disease and antiretroviral
therapy (ART) have led to a prolonged disease-free survival in a
substantial majority of HIV-infected individuals [1,2]. In parallel
with these therapeutic advances, it has become clear that some
ART also have serious adverse effects both in the short and long
term [3,4]. Cardiovascular disease (CVD) is now a leading cause of
death among HIV-infected individuals and rates of CVD appear
to be increased in HIV versus non-HIV infected groups [5–7].
Reports from the D:A:D study implicated ART, and protease
inhibitor (PI) use in particular, as a possible determinant of CVD
risk [8,9].
Findings from the Strategies for Management of Anti-Retroviral
Therapy (SMART) trial fueled interest in the hypothesis that some
component of CVD risk may be a consequence of HIV infection
itself [10]. The SMART study was designed to examine
intermittent use of ART as a strategy to reduce toxicities,
including CVD risk. However, despite one-third less antiretroviral
drug exposure, intermittent use of ART led to an increased CVD
risk compared to continuous use of ART [11].
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Studies have shown that HIV replication is an important
determinant of endothelial dysfunction [12,13]. Immune activa-
tion and inflammation may explain some of the excess cardiovas-
cular risk associated with HIV [14,15]. As a consequence of
impaired endothelial function and inflammation, HIV-infected
individuals may also be in a hypercoagulable state [16]. In
previous SMART reports, we showed that baseline levels of IL-6,
hsCRP and D-dimer were all strongly related to all-cause mortality
[17], and that IL-6 and hsCRP, but not D-dimer, were associated
with the development of AIDS events [18]. In this SMART report
we examine the association of these biomarkers with CVD
morbidity and mortality.
Methods
Ethics Statement
Prior to randomization, patients were asked to consent to
storing blood for future research. The SMART study, including
the consent for stored specimens, was approved by the institutional
review board or ethics committee of each clinical site and of the
University of Minnesota.
Design
The design, methods and results of the SMART trial have been
previously published [10]. Between January 2002 and January
2006, 5,472 HIV-infected patients with a CD4+ T cell count
.350 cells/mm3 were randomized to intermittent ART (drug
conservation, DC) or continuous ART (viral suppression, VS). For
patients in the DC group, ART was not used until the CD4+
count declined to ,250 cells/mm3, at which time ART was
initiated (or reinitiated) until the CD4+ count increased to more
than 350 cells/mm3. VS patients were to use available ART in an
uninterrupted manner with the goal of maximal and continuous
suppression of HIV replication. As previously reported on January
11, 2006, enrollment was stopped and participants in the DC
group were advised to restart ART. All participants were followed
until July 11, 2007 (study closure) [19], resulting in a minimum
follow-up of 18 months for each participant and a median follow-
up of 29 months.
Biomarkers and Cardiovascular Outcomes
CVD events occurring through study closure were reviewed
by an Endpoint Review Committee using pre-specified criteria
blinded to treatment group [20]. The CVD composite outcome
used in this report includes: CVD death, non-fatal myocardial
infarction (MI) (clinical and silent as measured by annual resting
ECG), non-fatal stroke, congestive heart failure (CHF), coronary
revascularization, coronary artery disease requiring drug treat-
ment, and peripheral arterial disease. Cause of death was
determined using the Coding of Death in HIV (CoDe) system
[21]. In this report, 19 deaths of unknown causes that were
unwitnessed were considered CVD on the assumption that most
would be CVD-related. These unwitnessed deaths do not
include violent deaths and deaths attributed to suicide,
substance abuse, and accidents by the Endpoint Review
Committee. In selected analyses, CVD events are grouped as
non-fatal coronary heart disease (CHD) (MI, coronary revascu-
larization, and coronary artery disease requiring drug treat-
ment), non-fatal atherosclerotic non-CHD (stroke and peripheral
vascular disease), congestive heart failure (CHF) and CVD
death.
Based on strong associations of hsCRP, IL-6 and D-dimer
with all-cause mortality in a nested case-control study [17] and
the observation that these biomarkers were elevated in HIV-
infected participants compared to those in the general popula-
tion [22], these three markers were measured on stored plasma
at baseline for all consenting participants by the Laboratory for
Clinical Biochemistry Research at the University of Vermont.
IL-6 was measured with Chemiluminescent Sandwich enzyme-
linked immunosorbent assay (R&D Systems, Minneapolis, MN);
hsCRP with a NMTM II nephelometer, N Antiserum to Human
CRP (Siemens Diagnostics, Deerfield, IL); and D-dimer levels
with immunoturbidometric methods on the Sta-R analyzer,
Liatest D-DI (Diagnostica Stago, Parsippany, NJ). Lipids were
centrally measured on serum by Quest Diagnostics, Inc. Lipids
were measured on the Olympus AU5400. LDL cholesterol was
directly measured. Fasting status influences triglyceride levels
but has little effect on total and HDL cholesterol levels; 52% of
sample obtained at baseline were fasting. Biomarkers and lipids
were analyzed blinded to CVD event status and treatment
group.
Statistical Methods
Time-to-event methods (Cox regression and Kaplan-Meier
curves) were used to study associations of baseline levels of each
biomarker with the CVD event. Our primary analysis focuses on
the DC and VS groups combined. Separate analyses by quartile of
each biomarker (defined using the entire cohort) were performed
and hazard ratios (HRs) for each of the three upper quartiles
versus the lowest quartile (reference group) are cited along with
95% confidence intervals (CIs). In addition to models that
categorized the three biomarkers according to quartiles, models
with log10 transformed biomarkers were considered and the
parameter estimates were used to determine the increase in risk of
CVD associated with a one standard deviation (SD) higher
biomarker level. Adjusted HRs were obtained by considering the
following covariates: age, gender, race, ART use, plasma HIV
RNA level, CD4+ count, prior AIDS diagnosis, smoking, BMI,
prior CVD, diabetes, hypertension treatment, hyperlipidemia
treatment, total/HDL cholesterol, presence of major ECG
abnormalities [23], hepatitis B or C co-infection and treatment
group.
HRs for different types of CVD events and analyses that
considered multiple CVD events per patient were also carried out.
The consistency of HRs for the different types of events associated
with each biomarker were assessed with chi-square [24]. Separate
analyses were also considered for the DC and VS groups
separately, and results from models that included an interaction
term between treatment group and log10 biomarker levels are
cited.
To determine whether the addition of IL-6, hsCRP, and D-
dimer to other CVD risk factors and HIV-related measurements
(i.e., the covariates cited above), improved model fit and risk
prediction, we carried out a 3 degree of freedom likelihood ratio
test and compared area under the receiver operating charac-
teristic curve (AUC) (c index) for the model that included the
three biomarkers plus baseline covariates mentioned above and
for the model that only included the baseline covariates. The
AUC for censored data estimates the probability that, of two
randomly chosen patients, that the patient with the higher
prognostic score remains free of CVD longer [25]. We used a
method for estimating AUC after 29 months (the median
follow-up of the cohort) described by Chambless and Diao
(method 1 in their report) [26]. Statistical analyses were
performed using SAS (Version 9.2, Carey, NC). All reported
p-values are 2-sided; p,0.05 is considered statistically signifi-
cant.
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Results
During a median follow-up of 29 months, 252 participants
experienced at least one CVD event. Numbers experiencing each
type of event were: CVD death (n= 44), non-fatal MI (n = 67),
non-fatal stroke (n = 20), CHF (n= 30), coronary revascularization
(n = 63), coronary artery disease requiring drug treatment (n = 51),
and peripheral arterial disease (n = 51). Fifty-four participants
experienced more than one CVD event. Table 1 summarizes
differences in major CVD risk factors and HIV-related factors for
participants with and without CVD events. P-values correspond-
ing to univariate associations and to associations that adjust for age
and gender are shown. hsCRP, IL-6 and D-dimer were associated
with an increased risk of CVD in both the univariate and age and
gender adjusted analyses. Kaplan-Meier curves for quartiles
(quartile cut-points are given in figure legend) of each biomarker
show good separation of the four curves for IL-6 and for the upper
two quartiles versus the lower two quartiles for hsCRP and D-
dimer (Figure 1).
In a regression model that included all three biomarkers and
baseline covariates used for adjustment (see Methods), higher
levels of IL-6 (p,0.001), hsCRP (p= 0.003), and D-dimer
(p = 0.002), older age (p,0.001), male gender (p = 0.04), higher
CD4+ T cell count (p = 0.02), prior AIDS (p= 0.01), smoking
(p = 0.002), prior CVD (p= 0.02), diabetes (p = 0.05), antihyper-
tensive therapy (p,0.001), and the presence of major ECG
abnormalities (p = 0.03) were associated with an increased risk of
CVD. The addition of the three biomarkers to the model that
included other baseline covariates significantly improved model fit
(likelihood ratio X2(3df) = 52.2; p,0.001. AUC estimates at 29
months based on models without and with the three biomarkers
were 0.741 and 0.771 (p,0.001 for difference). The two ROC
curves are shown in Figure 2. The ‘‘basic’’ model refers to the
model based on the covariates used for adjustment and cited in
Methods and in the figure legend. The ‘‘extended’’ model includes
all of the covariates in the ‘‘basic’’ model plus the three
biomarkers.
Table 2 gives adjusted HRs of CVD for each biomarker
considered separately. Risk gradients with CVD were evident for
each biomarker in the quartile analysis and also for the models
which treated each biomarker as a continuous variable. For the
latter analysis, for each biomarker, a 1 standard deviation (SD)
higher level was associated with approximately a 40% increased
risk of CVD. As a sensitivity analysis, we repeated these analyses
excluding the 19 unwitnessed deaths. The findings were almost
identical as those shown in Table 2. For example, adjusted HRs
associated with a 1 SD higher level of IL-6, hsCRP, and D-dimer
were 1.39 (95% CI: 1.25–1.55), 1.43 (95% CI: 1.23–1.65), and
1.38 (95% CI: 1.19–1.60), respectively.
Associations between IL-6, hsCRP and D-dimer and CVD were
similar for the DC and VS groups. Interaction p-values for
treatment and log-transformed biomarker levels were 0.39, 0.31,
and 0.87 for IL-6, hsCRP, and D-dimer, respectively. Adjusted
HRs for 1 SD higher IL-6, hsCRP, and D-dimer were 1.34 (95%
CI: 1.17–1.53), 1.57 (95% CI: 1.30–1.89), and 1.35 (95% CI:
1.11–1.64) for DC participants and 1.55 (95% CI: 1.29–1.86), 1.25
(95% CI: 1.01–1.55), and 1.43 (95% CI: 1.16–1.76) for VS
participants.
For each biomarker, associations with different types of CVD
event did not vary (p = 0.10 for IL-6, p = 0.45 for hsCRP, and
p= 0.15 for D-dimer). In an analysis that considered multiple
events per patient the adjusted HRs per 1 SD higher level of the
biomarker were 1.36 (p,0.001), 1.47 (p,0.001) and 1.43
(p,0.001) for IL-6, hsCRP and D-dimer respectively. Most events
were CHD. Adjusted HRs per 1 SD higher level of each
biomarker for fatal and non-fatal CHD events or unwitnessed
death (n = 160) were 1.37 (1.17, 1.59; p,0.001) for IL-6, 1.18
(1.00, 1.40; p= 0.05) for hsCRP and 1.33 (1.10, 1.61; p = 0.003)
for D-dimer. Adjusted HRs comparing the 4th versus 1st quartile
for this outcome were 5.23 (p,.001), 1.80 (p= 0.03), and 1.76
(p = 0.06), for IL-6, hsCRP, and D-dimer, respectively.
The joint relationship between IL-6 and D-dimer and between
hsCRP and D-dimer with CVD were also considered (Table 3).
After log transformation, the correlations between IL-6 and D-
dimer and between hsCRP and D-dimer were 0.33 (p,0.001) and
0.20 (p,0.001), respectively. The correlation between IL-6 and
hsCRP was 0.47 (p,0.001). When both IL-6 and D-dimer are
above the median level the adjusted HR versus those with both IL-
6 and D-dimer below the median was 3.96 (95% CI: 2.41–6.51).
The p-value for interaction between IL-6 and D-dimer was 0.06.
When both hsCRP and D-dimer were considered their effects on
CVD risk were additive (p = 0.72 for interaction). When either of
hsCRP or D-dimer was above the median risk was increased about
2-fold compared to those with both markers below the median.
When both hsCRP and D-dimer were above the median level the
adjusted HR versus those with levels below the median was 3.28
(95% CI: 2.04–5.28).
Discussion
Elevated baseline levels of IL-6, hsCRP and D-dimer were
significantly related to CVD and these associations remained after
adjustment for CVD risk factors and when considered jointly. The
associations of IL-6, hsCRP and D-dimer with different types of
CVD events did not differ. Although hyperlipidemia has clearly
been linked to the development of atherosclerosis, the potential
role of inflammatory mechanisms in the initiation, progression and
rupture of the atheromatous plaque has been appreciated only the
last decade [27,28]. A wide range of infections have been
associated with persistent inflammation, which itself has been
hypothesized to accelerate atherosclerosis [29]. Untreated HIV
infection is characterized by increased levels of pro-inflammatory
cytokines such as IL-6 and hsCRP, and increased expression of
adhesion molecules, factors identified to be important in the
pathogenesis of atherosclerosis [14]. These findings suggest that
HIV-associated inflammation and associated thrombosis and
fibrinolysis are determinants of CVD risk in individuals infected
with HIV [30,31].
Inflammatory cascades are propagated by proximal mediators
such as IL-6, which exerts pro-inflammatory effects including
stimulation of the liver to produce positive acute-phase proteins
during tissue injury or infection. Initially, epidemiological studies
of coronary heart disease (CHD) and inflammation focused on
‘‘downstream’’ acute phase reactants, e.g., fibrinogen and hsCRP.
In a meta-analysis of 160,309 participants, after adjustment for
other CVD risk factors a 1 SD higher CRP level was associated
with a 37% higher risk of CHD death, a 55% higher risk of CVD
death and a 43% higher risk of non-CVD death [32]. In SMART,
a 1 SD higher hsCRP was associated with an 18% increased risk of
fatal or non-fatal CHD and a 57% increased risk of fatal or non-
fatal CVD. In a previous report, we found that higher levels of
hsCRP were significantly related to all-cause mortality [17].
More recently there have been several prospective studies of IL-
6 and CHD. In an overview of studies of IL-6 and CHD, a 1 SD
higher level of IL-6 was associated with a 26% increased risk [33].
In SMART, a 1 SD higher level was associated with a 39%
increased risk of our CVD composite and a 37% increased risk of
fatal or non-fatal CHD. In that overview, the authors noted that
Inflammation, Coagulation and CVD in HIV
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due to within-person variability (biologic and laboratory variabil-
ity) the risk of CHD associated with IL-6 was underestimated.
With adjustment for this regression dilution bias, they found an
83% increased risk of CHD associated with a 1 SD higher IL-6.
The associations we report in SMART are also likely attenuated.
It has been suggested that modestly elevated circulating D-
dimer values reflect minor increases in blood coagulation,
thrombin formation, and turnover of cross-linked intravascular
fibrin and that these increases may be relevant to CHD. D-dimer
values may also reflect inflammatory states. In a meta-analysis of
D-dimer and CHD, the adjusted odds ratio (upper versus lowest
tertile of D-dimer) was 1.79 (95% CI, 1.36 to 2.36) [34]. In our
study, risk ratios for the 4th versus 1st quartile were 1.76 for fatal or
non-fatal CHD and 2.14 for our CVD composite. In SMART the
risk ratios associated with higher D-dimer levels for CVD were
much smaller than previously reported risk ratios for all cause
mortality [17]. In this respect our findings are similar to findings in
older participants in the Multiethnic Study of Atherosclerosis
(MESA) [35]. In that report, 6,391 participants were followed for
an average of 4.6 years and 307 CVD events, 207 CHD events
Figure 1. Kaplan-Meier Curves of Cardiovascular Disease (CVD) Events for Interleukin-6 (IL-6), High Sensitivity C-Reactive Protein
(hsCRP) and D-dimer. Cumulative percent of participants developing CVD by quartile of IL-6 (percentile cut-off points for IL-6 quartiles are: ,1.10,
1.10–1.76, 1.77–3.01,.3.01 pg/mL) (top); cumulative percent of participants developing CVD by quartile of hsCRP (percentile cut-off points for hsCRP
quartiles are: ,0.72, 0.72–1.71, 1.72–4.17, .4.17 mg/mL) (middle); cumulative percent of participants developing CVD by quartile of D-dimer
(percentile cut-off points for D-dimer quartiles are: ,0.13, 0.13–0.21, 0.22–0.37, .0.37 mg/mL) (bottom).
doi:10.1371/journal.pone.0044454.g001
Table 1. Baseline characteristics: Demographics, HIV factors, CVD risk factors and biomarkers for SMART participants who
developed a CVD event and those who did not.
Participants with CVD
event (N=252)
Participants without CVD event
(N=4846) p-value1 p-value2
Treatment group (% DC) 56.3 49.8 0.04 0.04
Demographics
Age (median, IQR) 49 (44, 56) 43 (38, 50) ,0.001 NA
Gender (% female) 19.0 26.3 0.02 NA
Black (%) 39.7 28.7 0.02 0.003
Injection drug use (%) 13.1 9.9 0.36 0.30
CD4+ (cells/mm3) (median, IQR) 579 (458, 858) 600 (468, 792) 0.12 0.11
CD4+ nadir (cells/mm3) (median, IQR) 236 (120, 350) 252 (157, 360) 0.13 0.44
HIV-RNA #400 copies/mL (%) 67.7 71.2 0.77 0.60
Prior AIDS-related illnesses (%) 36.5 23.9 ,0.001 ,0.001
Hepatitis B (%) 2.0 2.5 0.59 0.64
Hepatitis C (%) 20.2 15.0 0.09 0.13
CVD Risk Factors
Current smoker (%) 52.4 40.9 ,0.001 ,0.001
Diabetes (%) 17.1 6.6 ,0.001 ,0.001
Prior CVD (%) 13.1 3.2 ,0.001 ,0.001
Major ECG abnormality (%) 21.1 8.7 ,0.001 ,0.001
Blood pressure lowering drugs(%) 44.4 18.0 ,0.001 ,0.001
Lipid lowering drugs (%) 27.8 15.6 ,0.001 0.04
BMI (kg/m2) (median, IQR) 25.7 (22.3, 28.9) 25.0 (22.5, 28.1) 0.75 0.34
Lipids
Total cholesterol (mg/dL) (median, IQR) 197 (171, 233) 191 (163, 221) 0.003 0.08
HDL cholesterol (mg/dL) (median, IQR) 38 (31, 49) 41 (33, 51) 0.03 0.04
LDL cholesterol (mg/dL) (median, IQR) 111 (89, 141) 112 (90, 135) 0.27 0.66
Triglycerides (mg/dL) (median, IQR) 192 (134, 308) 163 (105, 260) 0.05 0.30
Total/HDL cholesterol (median, IQR) 5.2 (3.9, 6.8) 4.6 (3.6, 5.9) ,0.001 0.005
Inflammation and Coagulation Biomarkers
hsCRP (mg/mL) (median, IQR) 3.34 (1.47, 7.51) 1.67 (0.70, 4.02) ,0.001 ,0.001
IL-6 (pg/mL) (median, IQR) 3.07 (1.87, 4.83) 1.72 (1.07, 2.92) ,0.001 ,0.001
D-dimer (mg/mL) (median, IQR) 0.31 (0.18, 0.59) 0.20 (0.13, 0.36) ,0.001 ,0.001
1P-values from univariate Cox models.
2P-values adjusted for age and gender. Log10 transformed levels were used for biomarker analyses.
CVD: Cardiovascular Disease, DC: Drug Conservation, BMI: Body Mass Index, NA: not applicable.
doi:10.1371/journal.pone.0044454.t001
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and 210 deaths were observed. Age, sex, race and risk-factor
adjusted hazard ratios for the the 4th versus 1st quartile of D-dimer
were 1.08 (95% CI: 0.75–1.55) for CVD, 1.27 (95% CI: 0.80–
2.01) for CHD, and 2.57 (95% CI: 1.54–4.27) for all-cause
mortality. There have been few studies examining the association
of D-dimer with CVD in HIV-infected participants. In a case-
control study of 52 CVD events, Ford et al. found that D-dimer
levels but not hsCRP or IL-6 levels were significantly elevated 4
months and 2 years prior to developing the CVD event as
compared to matched controls [36].
Even though treatment interruption led to an increase in IL-6,
hsCRP and D-dimer and treatment initiation led to a decline in D-
dimer [14,37], associations of these markers at baseline with the
development of CVD events were similar for DC and VS patients.
We have previously shown that these markers are elevated even in
patients taking ART with a suppressed viral load [22]. This,
coupled with the fact that DC participants were advised to re-
initiate ART midway through the study, likely makes it difficult to
detect any differences in baseline associations of these markers
with risk of CVD that might have been influenced by changes
during follow-up. Further research is needed on serial patterns of
these markers with different clinical outcomes.
Even though the likelihood-based method of model fit indicated
significant improvement (p,0.001) with the addition of the three
biomarkers to a model that included other CVD and HIV risk
factors, the improvement in CVD risk discrimination as measured
by the AUC was modest. Further research on the utility of these
biomarkers for classifying participants by CVD risk is needed,
including risk reclassification methods with the models described
here applied to other cohorts.
There are some limitations of this analysis. We studied the
association of a single measurement of the inflammatory markers
Figure 2. Receiver-Operating Characteristic (ROC) Curve for ‘‘Basic’’ and ‘‘Extended’’ Models for 29 Month Risk of Cardiovascular
Disease (CVD) in SMART. The ‘‘basic’’ model included the following baseline covariates: age, gender, race, ART use, plasma HIV RNA level, CD4+
cell count, prior AIDS diagnosis, smoking, BMI, prior CVD, diabetes, hypertension treatment, hyperlipidemia treatment, total/HDL cholesterol,
presence of major ECG abnormalities, hepatitis B or C co-infection and treatment group. The ‘‘extended’’ model includes these covariates plus hsCRP,
IL-6 and D-dimer after log10 transformation.
doi:10.1371/journal.pone.0044454.g002
Table 2. Hazard ratios for cardiovascular disease (CVD) associated with baseline biomarker levels.
IL-6 hsCRP D-dimer
Biomarker
Quartile1
No. with CVD
(Rate per 100
person years)
Adjusted HR2
(95% CI)
No. with CVD
(Rate per 100
person years)
Adjusted HR2
(95% CI)
No. with CVD
(Rate per 100
person years)
Adjusted HR2
(95% CI)
Lowest 16 (0.5) 1.00 37 (1.1) 1.00 34 (1.1) 1.00
2nd 35 (1.0) 1.68 (0.88–3.18) 36 (1.0) 0.91 (0.57–1.48) 44 (1.2) 1.14 (0.71–1.83)
3rd 67 (1.9) 2.81 (1.55–5.08) 68 (2.0) 1.46 (0.95–2.23) 66 (1.9) 1.57 (1.00–2.46)
Highest 122 (3.5) 4.65 (2.61–8.29) 110 (3.2) 2.10 (1.40–3.16) 105 (2.9) 2.14 (1.38–3.33)
HR2 associated with 1
SD3 higher (95% CI)
1.39 (1.25–1.54) 1.43 (1.24–1.64) 1.40 (1.21–1.61)
1Quartile cut-points are given in the legend for Figure 1.
2Adjusted for age, gender, race, ART, plasma HIV RNA level, CD4+ T cell count, prior AIDS diagnosis, smoking, BMI, prior CVD, diabetes, hypertension treatment,
hyperlipidemia treatment, total/HDL cholesterol, ECG abnormalities, hepatitis B or C co-infection, and treatment group.
3Standard deviations (SDs) after log10 transformation were 0.34 pg/mL for IL-6, 0.54 mg/mL for hsCRP, and 0.42 mg/mL for D-dimer.
doi:10.1371/journal.pone.0044454.t002
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and coagulation factor at the beginning of the study with CVD.
Thus, associations reported are likely underestimated. Also, we
studied only a limited number of biomarkers from the inflamma-
tory and thrombotic/fibrinolysis pathways. Strengths of this study
are that CVD outcomes were pre-specified and adjudicated by an
endpoint review committee and adjustment for most major CVD
risk factors was possible.
In conclusion, this study demonstrated that thrombosis and
inflammation are inextricably intertwined in the biology of
atherosclerosis in HIV-infected individuals. The current findings
do not, of course, establish causality, but they may have
implications for understanding disease mechanisms and for further
research strategies [38]. Further studies are warranted to
determine if therapies that result in lowering of these biomarkers
lead to reductions in risk of CVD.
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